Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COM503 + zimberelimab
- Development stage
- Unknown
- Lead developer
- Compugen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
COM503 + zimberelimab is an experimental combination therapy under investigation for the treatment of advanced solid tumors. COM503 is a potential first-in-class monoclonal antibody targeting interleukin-18 binding protein (IL-18BP), designed to release endogenous IL-18 to potentiate anti-tumor immune responses within the tumor microenvironment. Zimberelimab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) immune checkpoint, enabling the immune system to recognize and attack cancer cells. The combination is being evaluated for its ability to enhance anti-tumor immunity by simultaneously unleashing IL-18 activity and blocking PD-1-mediated immune suppression[1][2][3][5].
- Other names
- COM503 + zimberelimab
02
Targets
IL18BP (Interleukin-18 binding protein)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on COM503 + zimberelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COM503 + zimberelimab.